TheEdgeResearch
Home / Stocks / BITRF

Biotron Limited (BITRF)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$2.5M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.64
52-Wk Range
0.0011-0.0415
CEO
Michelle Miller GCertAppFin
Country
AU
Currency
USD

Biotron Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2.5M. On trailing twelve-month figures it carries a trailing P/E of -3.56, a net margin of 0.0%. Its beta of -0.64 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.56
Price / Sales
0.00
Price / Book
1.85
EV / EBITDA
-0.90
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
1.94
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2013-03-22
Headquarters
Sydney, NSW, AU
About Biotron Limited

Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.

Comparable companies

Biotron Limited is most often compared with the following Healthcare names:

BNGIBPTSYDYNTGRCUMCETMDNWFPFNDTSOIVIRXYECO
More research on BITRF
BITRF technical analysis BITRF TheEdge Score Compare against peers
Open full interactive analysis & DCF →